Herpes Zoster
Conditions
Keywords
Anxiety, Depression, Herpes Zoster, Neuralgia
Brief summary
The goal of this observational study is to explore risk factors of anxiety and depression in patients with herpes zoster neuralgia, and the changes of certain serum biomarkers and functional brain magnetic resonance images of these patients.
Detailed description
Patients with herpes zoster neuralgia will be recruited and take Hospital anxiety depression rating scale (Hospital anxiety and 'scale, HADS) evaluation. According to the HADS Scores, patients will be divided into depression group and no depression, or anxiety group and no anxiety group. The clinical data the of two groups will be collected and statistically analyzed to explore the risk factors of anxiety and depression, including the changes of serum biomarkers and functional brain magnetic resonance imaging in patients with herpes zoster neuralgia accompanying anxiety or depression.
Interventions
DIAGNOSTIC_TESTHospital Anxiety and Depression Scale
Hospital Anxiety and Depression Scale questionnaire is used to test patients for anxiety and depression.
Sponsors
Huazhong University of Science and Technology
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age more than 18 years old 2. Diagnosed as herpes zoster neuralgia 3. Signing informed consent
Exclusion criteria
1. Unable to complete the scale assessment 2. History of mental illness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HADS score | during hospital stay, average of 1 week | Enrolled patients will be first evaluated by Hospital Anxiety and Depression Scare questionaire and according to the HADS score, patients will be divided to group with anxiety/depression and group without anxiety/depression. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| IL-2 receptor plasma level | during hospital stay, average of 1 week | Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-2 （u/ml）will be tested. |
| IL-6 plasma level | during hospital stay, average of 1 week | Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-6 （pg/ml）will be tested. |
| IL-8 plasma level | during hospital stay, average of 1 week | Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-8 （pg/ml）will be tested. |
| IL-10 plasma level | during hospital stay, average of 1 week | Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-10 （pg/ml）will be tested. |
| Interleukin (IL）-1β plasma level | during hospital stay, average of 1 week | Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines IL-1β （pg/ml）will be tested. |
| Brain-derived neurotrophic factor (BDNF) plasma level | during hospital stay, average of 1 week | Blood sample will be obtained from enrolled patients and the plasma level of BDNF（pg/ml）will be tested. |
| C-reactive protein (CRP) plasma level | during hospital stay, average of 1 week | Blood sample will be obtained from enrolled patients and the plasma level of CRP（mg/ml）will be tested. |
| Area under curve (AUC) of topological metrics of functional brain magnetic resonance imaging | during hospital stay, average of 1 week | Functional brain magnetic resonance imaging will be performed in patients with anxiety or depression, and area under curve (AUC) of topological metrics including Eglob,Eloc,Cp,Lp,γ,λ and σ will be calculated and analyzed. |
| Interferon(INF)-α plasma level | during hospital stay, average of 1 week | Blood sample will be obtained from enrolled patients and the plasma level of inflammatory cytokines INF-α （pg/ml）will be tested. |
Countries
China
Contacts
Primary ContactYang Shuguang, M.D
Backup ContactMei wei, M.D, PhD
Outcome results
None listed